Furthermore, in the control group (patients not receiving any of the molecules above mentioned) A1c levels were higher, and it may be implied that factors other than glycaemic control may be responsible for the protective effects of GLP1-Ra and DPP-4i in patients with T2DM and COVID-19. This evidence concerns the gene GCG and type 2 diabetes mellitus.